GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » EV-to-FCF

RenovoRx (RenovoRx) EV-to-FCF : -2.64 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is RenovoRx EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, RenovoRx's Enterprise Value is $25.79 Mil. RenovoRx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.76 Mil. Therefore, RenovoRx's EV-to-FCF for today is -2.64.

The historical rank and industry rank for RenovoRx's EV-to-FCF or its related term are showing as below:

RNXT' s EV-to-FCF Range Over the Past 10 Years
Min: -21.12   Med: 0   Max: 0
Current: -2.64

RNXT's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs RNXT: -2.64

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), RenovoRx's stock price is $1.26. RenovoRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.720. Therefore, RenovoRx's PE Ratio for today is At Loss.


RenovoRx EV-to-FCF Historical Data

The historical data trend for RenovoRx's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx EV-to-FCF Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -4.73 -1.70 -2.27

RenovoRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.98 -1.85 -1.11 -2.27 -1.87

Competitive Comparison of RenovoRx's EV-to-FCF

For the Biotechnology subindustry, RenovoRx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovoRx's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where RenovoRx's EV-to-FCF falls into.



RenovoRx EV-to-FCF Calculation

RenovoRx's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=25.790/-9.756
=-2.64

RenovoRx's current Enterprise Value is $25.79 Mil.
RenovoRx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovoRx  (NAS:RNXT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

RenovoRx's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.26/-0.720
=At Loss

RenovoRx's share price for today is $1.26.
RenovoRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.720.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


RenovoRx EV-to-FCF Related Terms

Thank you for viewing the detailed overview of RenovoRx's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovoRx (RenovoRx) Business Description

Traded in Other Exchanges
N/A
Address
4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.
Executives
Angela Nelms officer: Chief Operating Officer C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers officer: Chief Financial Officer 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah director, officer: Chief Medical Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai director, officer: Chief Executive Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West 10 percent owner PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman officer: Chief Financial Officer 65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners officer: Chief Financial Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303